2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Mouse |
| Synonyms | Interferon lambda-2; IFN-lambda-2; Interleukin-28A; IL-28A; |
| Accession | Q4VK74 |
| Amino Acid Sequence | Asp20-Val193 |
| Expression System | E.coli |
| Molecular Weight | 20 kDa (Reducing) |
| Purity | >95% by SDS-PAGE and HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | 20mM Tris, 150mM NaCl, pH8.0 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | Nat Immunol. 2003 Jan;4(1):63-8. |
Background
Interferon lambda 2 (IFN-λ2), also known as IL-28A, is a member of the type III interferon family, which also includes IFN-λ1 and IFN-λ3. IFN-λ2 plays a crucial role in the innate immune response to viral infections and has been shown to exhibit antiviral activity against a variety of viruses, including hepatitis C virus, influenza virus, and others. It signals through the IFN-λ receptor complex, leading to the activation of JAK-STAT signaling pathways and the induction of interferon-stimulated genes (ISGs) that contribute to the antiviral defense mechanisms. IFN-λ2 is primarily produced by immune cells, such as dendritic cells and macrophages, in response to viral stimuli and functions as a key mediator of the host's defense against viral pathogens.
Picture
Picture
SDS-PAGE
SEC-HPLC
>95% as determined by SEC-HPLC.
